Patents by Inventor Gerald McMahon

Gerald McMahon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method and compositions for inhibition of adaptor protein/tyrosine kinase interactions
    Publication number: 20020016353
    Abstract: The present invention relates to methods and compositions for the inhibition of adaptor protein/protein tyrosine kinase protein interactions, especially wherein those interactions involving a protein tyrosine kinase capable of complexing with a member of the SH2- and/or SH3-containing family of adaptor proteins are associated with a cell proliferative disorder. Specifically, the present invention relates to particular compounds, especially quinazoline derivative compounds, and methods utilizing such compounds.
    Type: Application
    Filed: May 14, 2001
    Publication date: February 7, 2002
    Inventors: Peng Cho Tang, Gerald McMahon, G. Davis Harris
  • Methods of modulating c-kit tyrosine protein kinase function with indolinone compounds
    Publication number: 20020010203
    Abstract: The present invention concerns compounds and their use to inhibit the activity of a receptor tyrosine kinase. The invention is preferably used to treat cell proliferative disorders such as cancers characterized by over-activity or inappropriate activity c-kit kinase.
    Type: Application
    Filed: December 22, 2000
    Publication date: January 24, 2002
    Inventors: Ken Lipson, Gerald McMahon
  • 3-(Cycloalkanoheteroarylidenyl)-2-Indolinone Protein Tyrosine Kinase Inhibitors
    Publication number: 20010056094
    Abstract: The present invention relates to novel 3-(cycloalkano-heteroarylidenyl)-2-indolinone compounds and physiologically acceptable salts and prodrugs thereof which are expected to modulate the activity of protein tyrosine kinases and therefore to be useful in the prevention and treatment of protein tyrosine kinase related cellular disorders such as cancer.
    Type: Application
    Filed: January 12, 2000
    Publication date: December 27, 2001
    Inventors: Peng Cho Tang, Li Sun, Gerald McMahon
  • Tricyclic quinoxaline derivatives as protein tyrosine kinase inhibitors
    Patent number: 6329375
    Abstract: The present invention relates to tricyclic quinoxaline compounds and physiologically acceptable salts and prodrugs thereof which modulate the activity of protein tyrosine kinases and therefore should be useful in the prevention and treatment of protein tyrosine kinase related cellular disorders such as cancer.
    Type: Grant
    Filed: August 4, 1998
    Date of Patent: December 11, 2001
    Assignee: Sugen, Inc.
    Inventors: Peng Cho Tang, Li Sun, Gerald McMahon
  • 2-indolinone derivatives as modulators of protein kinase activity
    Patent number: 6316635
    Abstract: The present invention relates to novel imidazoly 2-indolinones and physiologically acceptable salts and prodrugs thereof which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.
    Type: Grant
    Filed: April 15, 1999
    Date of Patent: November 13, 2001
    Assignee: Sugen, Inc.
    Inventors: Peng Cho Tang, Li Sun, Gerald McMahon, G. David Harris
  • Isoxazole-4-carboxamide compounds active against protein tryosine kinase related disorders
    Patent number: 6316479
    Abstract: The present invention relates to novel isoxazole-4-carboxamides which modulate the activity of protein tyrosine kinases and therefore are expected to be useful in the treatment of abnormal protein tyrosine kinase activity driven disorders including cancer.
    Type: Grant
    Filed: May 19, 1998
    Date of Patent: November 13, 2001
    Assignee: Sugen, Inc.
    Inventors: Gerald McMahon, Peng Cho Tang, Laura Kay Shawver, Klaus Peter Hirth
  • Bicyclic protein kinase inhibitors
    Patent number: 6316429
    Abstract: The present invention relates to novel 3-idene-2-indolinone compounds and physiologically acceptable salts thereof which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.
    Type: Grant
    Filed: May 7, 1998
    Date of Patent: November 13, 2001
    Assignee: Sugen, Inc.
    Inventors: Peng Cho Tang, Li Sun, Gerald McMahon
  • Bioavailability of 3-heteroarylidenyl-2-indolinones active as protein tyrosine kinase inhibitors
    Patent number: 6313158
    Abstract: The present invention relates to novel 3-heteroarylidenyl-2-indolinone compounds and physiologically acceptable salts and prodrugs thereof which have improved hydrosolubility and which are expected to modulate the activity of protein tyrosine kinases and therefore should be useful in the prevention and treatment of protein tyrosine kinase related cellular disorders such as cancer.
    Type: Grant
    Filed: June 19, 1998
    Date of Patent: November 6, 2001
    Assignee: Sugen, Inc.
    Inventors: Peng Cho Tang, Li Sun, Gerald McMahon
  • 3-(4'-bromobenzylindenyl)-2-indolinone and analogues thereof for the treatment of disease
    Publication number: 20010027207
    Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Application
    Filed: January 22, 2001
    Publication date: October 4, 2001
    Inventors: Peng Cho Tang, Li Sun, Gerald McMahon
  • Methods of modulating serine/threonine protein kinase function with quinazoline-based compounds
    Publication number: 20010014679
    Abstract: The present invention is directed in part towards methods of modulating the function of serine/threonine protein kinases with quinazoline-based compounds. The methods incorporate cells that express a serine/threonine protein kinase, such as RAF. In addition, the invention describes methods of preventing and treating serine/threonine protein kinase-related abnormal conditions in organisms with a compound identified by the invention. Furthermore, the invention pertains to quinazoline compounds and pharmaceutical compositions comprising these compounds.
    Type: Application
    Filed: January 26, 2001
    Publication date: August 16, 2001
    Inventors: Peng C. Tang, Gerald McMahon, Heinz Weinberger, Bernhard Kutscher, Harald App
  • Novel 3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity
    Publication number: 20010007033
    Abstract: The present invention relates to novel 3-(substituted)-2-indolinones compounds and physiologically acceptable salts and prodrugs thereof which modulate the activity of protein kinases and therefore are expected to e useful in the prevention and treatment of protein kinase related disorders such as cancer.
    Type: Application
    Filed: March 1, 2000
    Publication date: July 5, 2001
    Inventors: Peng Cho Tang, Li Sun, Gerald McMahon
  • Method and compositions for inhibition of adaptor protein/tyrosine kinase interactions
    Patent number: 6239161
    Abstract: The present invention relates to methods and compositions for the inhibition of adaptor protein/protein tyrosine kinase protein interactions, especially wherein those interactions involving a protein tyrosine kinase capable of complexing with a member of the SH2-and/or SH3-containing family of adaptor proteins are associated with a cell proliferative disorder. Specifically, the present invention relates to particular compounds, especially quinazoline derivative compounds, and methods utilizing such compounds.
    Type: Grant
    Filed: May 5, 2000
    Date of Patent: May 29, 2001
    Assignee: Sugen, Inc.
    Inventors: Peng Cho Tang, Gerald McMahon, G. Davis Harris
  • Tyrphostin like compounds
    Patent number: 6225346
    Abstract: The present invention relates to molecules capable of modulating tyrosine signal transduction to prevent and treat cell proliferative disorders or cell differentiation disorders associated with particular tyrosine kinases by inhibiting one or more abnormal tyrosine kinase activities.
    Type: Grant
    Filed: August 10, 1999
    Date of Patent: May 1, 2001
    Assignee: Sugen, Inc.
    Inventors: Peng Cho Tang, Li Sun, Asaad S. Nematalla, Gerald McMahon
  • 3-(4?-bromobenzylindenyl)-2-indolinone and analogues thereof for the treatment of disease
    Patent number: 6225335
    Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Grant
    Filed: December 15, 1998
    Date of Patent: May 1, 2001
    Assignee: Sugen, Inc.
    Inventors: Peng Cho Tang, Li Sun, Gerald McMahon
  • Methods of modulating serine/thereonine protein kinase function with quinazoline-based compounds
    Patent number: 6204267
    Abstract: The present invention is directed in part towards methods of modulating the function of serine/threonine protein kinases with quinazoline-based compounds. The methods incorporate cells that express a serine/threonine protein kinase, such as RAF. In addition, the invention describes methods of preventing and treating serine/threonine protein kinase-related abnormal conditions in organisms with a compound identified by the invention. Furthermore, the invention pertains to quinazoline compounds and pharmaceutical compositions comprising these compounds.
    Type: Grant
    Filed: May 1, 1998
    Date of Patent: March 20, 2001
    Assignee: Sugen, Inc.
    Inventors: Peng C. Tang, Gerald McMahon, Heinz Weinberger, Bernhard Kutscher, Harald App
  • Methods of modulating serine/threonine protein kinase function with 5-azaquinoxaline-based compounds
    Patent number: 6180631
    Abstract: The present invention is directed in part towards methods of modulating the function of serine/threonine protein kinases with 5-azaquinoxaline-based compounds. The methods incorporate cells that express a serine/threonine protein kinase, such as RAF. In addition, the invention describes methods of preventing and treating serine/threonine protein kinase-related abnormal conditions in organisms with a compound identified by the invention. Furthermore, the invention pertains to 5-azaquinoxaline compounds and pharmaceutical compositions comprising these compounds.
    Type: Grant
    Filed: October 5, 1998
    Date of Patent: January 30, 2001
    Assignee: Asta Medica Aktiengesellschaft
    Inventors: Gerald McMahon, Heinz Weinberger, Bernhard Kutscher, Harald App
  • Indolinone combinatorial libraries and related products and methods for the treatment of disease
    Patent number: 6147106
    Abstract: The present invention relates to organic molecules capable of modulating, regulating and/or inhibiting protein kinase signal transduction. Such compounds are useful for the treatment of diseases related to unregulated protein kinase signal transduction, including cell proliferative diseases such as cancer, atherosclerosis, arthritis and restenosis and metabolic diseases such as diabetes. The present invention features indolinone compounds that potently inhibit protein kinases and related products and methods. Inhibitors specific to the FLK protein kinase can be obtained by adding chemical substituents to the 3-[(indole-3-yl)methylene]-2-indolinone, in particular at the 1' position of the indole ring. Indolinone compounds that specifically inhibit the FLK and platelet derived growth factor protein kinases can harbor a tetrahydroindole or cyclopentano-b-pyrrol moiety.
    Type: Grant
    Filed: August 20, 1997
    Date of Patent: November 14, 2000
    Assignee: Sugen, Inc.
    Inventors: Peng Cho Tang, Li Sun, Gerald McMahon, Klaus Peter Hirth, Laura Kay Shawver
  • Pharmaceutical compositions and methods for modulating signal transduction
    Patent number: 6143765
    Abstract: The present invention relates to organic molecules capable of inhibiting protein tyrosine phosphatase activity. The invention further relates to the use of such molecules to modulate or regulate signal transduction by inhibiting protein tyrosine phosphatase activity. Finally, the invention relates to the use of such molecules to treat various disease states including diabetes mellitus.
    Type: Grant
    Filed: July 21, 1998
    Date of Patent: November 7, 2000
    Assignee: Sugen, Inc.
    Inventors: Peng Cho Tang, Gerald McMahon
  • 3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity
    Patent number: 6133305
    Abstract: The present invention relates to novel 3-(substituted)-2-indolinones compounds and physiologically acceptable salts and prodrugs thereof which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related disorders such as cancer.
    Type: Grant
    Filed: September 25, 1998
    Date of Patent: October 17, 2000
    Assignee: Sugen, Inc.
    Inventors: Peng Cho Tang, Li Sun, Gerald McMahon
  • 3-(cyclohexanoheteroarylidenyl)-2-indolinone protein tyrosine kinase inhibitors
    Patent number: 6130238
    Abstract: The present invention relates to novel 3-(cyclohexanoheteroarylidenyl)-2-indolinone compounds and physiologically acceptable salts and prodrugs thereof which are expected to modulate the activity of protein tyrosine kinases and therefore to be useful in the prevention and treatment of protein tyrosine kinase related cellular disorders such as cancer.
    Type: Grant
    Filed: June 19, 1998
    Date of Patent: October 10, 2000
    Assignee: Sugen, Inc.
    Inventors: Peng Cho Tang, Li Sun, Gerald McMahon